clinical trial · NCT00129038
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
Boehringer Ingelheim·phase4·completed·n = 11
Coronary Arteriosclerosismodified-release dipyridamole/aspirinaspirin
brief summary
The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone
started
Apr 1, 2004
primary completion
Jan 1, 2007
completion
—
last updated
Jan 23, 2025
official title
A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol